(936 cases) regions, Candida albicans predominated (48.4%), followed by C. glabrata (18.0%), C. parapsilosis (17.2%), C. tropicalis (10.5%), and C. krusei (1.9%). Resistance to echinocandins (anidulafungin [2.4%] and micafungin [1.9%]) and azoles (3.5 to 5.6%) was most prevalent among C. glabrata isolates, as determined using recently established CLSI breakpoint criteria. C. glabrata isolates were more common in NAM (23.5%), and C. albicans isolates were more common in APAC (56.9%), with C. parapsilosis (25.6%) and C. tropicalis (17.0%) being more prominent in LAM. Emerging resistance patterns among C. glabrata cases in NAM require focused surveillance.
Among the systemically active antifungal agents with potencies against Candida spp., the echinocandins micafungin and anidulafungin were approved by the U.S. Food and Drug Administration (FDA) for the treatment of candidemia and other forms of invasive candidal infections in 2005 and 2006, respectively, and posaconazole was approved for the prevention of invasive fungal infections in 2006. Although the variation in Candida species causing bloodstream infection (BSI) and the frequency of resistance to fluconazole and voriconazole by geographic region have been described earlier (6, 15, 17) , similar data are lacking for anidulafungin, micafungin, and posaconazole. Given the widespread use of both the echinocandins and azoles, coupled with reports of emerging resistance to both of these classes of antifungal agents (10, 17, 19, 21) , there is a need for ongoing surveillance to monitor for evolving anidulafungin, micafungin, and posaconazole resistance among Candida isolates.
We have performed global antifungal surveillance to monitor trends in antifungal susceptibility of clinical isolates of Candida spp. since 1997 (18) . We now report recent (2008) (2009) (13) . The isolates were collected at individual study sites and were sent to JMI Laboratories (North Liberty, IA) for central reference laboratory identification and susceptibility testing as described previously (9) . The isolates were identified by standard methods and stored as water suspensions until used in the study. Before testing, each isolate was passaged at least twice on Sabouraud dextrose agar (Remel, Lenexa, KS) and CHROMagar Candida medium (Becton Dickinson, Sparks, MD).
Broth microdilution (BMD) testing was performed in accordance with the guidelines in CLSI document M27-A3 (4). MICs were determined visually after 24 h of incubation for anidulafungin, micafungin, and fluconazole and after 48 h for posaconazole and voriconazole as the lowest concentration of each drug that caused a significant diminution (Ն50%) of growth below control levels. We used the recently revised CLSI breakpoints to identify strains resistant to anidulafungin, micafungin, and fluconazole (12, 16) : anidulafungin and micafungin MIC values at Ͼ0.5 g/ml were defined as resistant for C. albicans, C. tropicalis, and C. krusei, and MIC values at Ͼ4 g/ml were considered resistant for C. parapsilosis; anidulafungin MICs at Ͼ0.5 g/ml and micafungin MIC values at Ͼ0.12 g/ml were defined as resistant for C. glabrata; fluconazole MIC results of Ͼ4 g/ml were declared resistant for C. albicans, C. tropicalis, and C. parapsilosis, and MIC values at Ͼ32 g/ml were considered resistant for C. glabrata. The CLSI resistance breakpoint for voriconazole (Ͼ2 g/ml) was also applied to posaconazole for all species (20) . Quality control was performed by testing the CLSI-recommended strains C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 (5) . Table 1 displays the species distribution of invasive Candida sp. isolates from 2008 to 2009. C. albicans was most common in the Asian-Pacific region (56.9%) and least common in North America (43.4%), whereas C. glabrata was most common in North America (23.5%) and least encountered in Latin America (5.2%). C. parapsilosis and C. tropicalis were most common in Latin America (25.6 and 17.0%, respectively), and C. krusei was more common in Europe (2.5%). No anidulafungin or micafungin resistance was detected in any species from the Asian-Pacific and Latin American regions (Table 2) . Similarly, no resistance to posaconazole or voriconazole was observed among isolates of C. albicans and C. parapsilosis from any region. Resistance to anidulafungin (3.2%), micafungin (2.7%), and the azoles (5.5 to 8.2%) was most prominent among iso- a Resistance is defined as an MIC Ͼ 0.5 g/ml for anidulafungin and micafungin versus C. albicans, C. tropicalis and C. krusei, an MIC Ͼ 4 g/ml versus C. parapsilosis, an MIC Ͼ 0.5 g/ml for anidulafungin and an MIC Ͼ 0.12 g/ml for micafungin and C. glabrata, an MIC Ͼ 4 g/ml for fluconazole versus C. albicans, C. tropicalis, and C. parapsilosis an MIC Ͼ 32 g/ml versus C. glabrata, and an MIC Ͼ 2 g/ml for posaconaole and voriconazole for all species. L., Latin; N., North.
b All isolates of C. krusei were defined as resistant to fluconazole as per CLSI criteria. Table 2 ). In addition to C. glabrata, resistance to fluconazole was observed in C. parapsilosis and C. tropicalis, respectively, from the Latin American (6.7 and 1.7%), European (3.9 and 3.6%), and North American (5.0 and 4.1%) regions. Voriconazole-resistant isolates were found for C. tropicalis from Latin America (1.7%), Europe (3.6%), and North America (2.0%). Crossresistance between fluconazole and voriconazole and between all three triazoles was seen among C. tropicalis isolates from Latin American, Europe, and North America, respectively. Table 3 provides a comparison of the MIC distribution for micafungin according to species of Candida collected before and after the clinical introduction of micafungin in North America. Results from the two time periods were obtained with CLSI reference methods in different laboratories; however, quality control procedures were rigorously performed during both studies, suggesting that testing conditions did not influence the differences noted.
Although no resistant strains of C. albicans or C. krusei were observed in either time period, a one doubling dilution shift toward a higher modal MIC was seen in 2008 and 2009 for both of these species. A similar shift was detected for C. glabrata with the emergence of six (2.7%) resistant strains. Even though the number of resistant C. glabrata strains was small, the recent report of five episodes of breakthrough fungemia (C. glabrata) on micafungin treatment with elevated MIC values (4 to 8 g/ml) and fks mutations suggests that this species requires monitoring with respect to both azole and echinocandin resistance (21) . The micafungin MIC distributions for C. parapsilosis were comparable in the two time periods, and although a shift was noted for C. tropicalis, no resistant strains of either species were detected in the most recent sample. It is noteworthy that in addition to cases of breakthrough fungemia due to micafungin-resistant C. glabrata, Pfeiffer et al. (21) also reported similar cases due to C. parapsilosis in patients receiving at least three doses of this echinocandin. None of the isolates of C. parapsilosis were found to harbor fks hot-spot mutations; however, MIC values of Ͼ2 g/ml were documented for five of the six isolates tested (21) . These investigators were unable to identify the echinocandin resistance mechanism in these C. parapsilosis isolates.
The BSI data for these contemporary Candida species confirm previous findings that both species distribution and antifungal resistance patterns vary across geographic regions. It is notable that although fluconazole resistance was detected in only a small proportion of C. albicans (0.1%), C. tropicalis (3.2%), and C. parapsilosis (5.0%) isolates, these species accounted for 34% of the 93 fluconazole-resistant isolates. This finding is similar to that of Oxman et al. (10) , who cautioned that simple species identification may not be sufficient to predict the fluconazole susceptibility patterns.
Although rates of resistance to anidulafungin, micafungin, and the azoles were quite low for all of the identified Candida species in the Asian-Pacific, Latin American, and European regions, the presence of resistance to both antifungal classes among North American BSI isolates of C. glabrata is a growing concern. Whereas azole resistance in North American C. glabrata isolates is well known (1, 11, 14) , the recent reports of isolates with echinocandin resistance due to fks mutations are most troubling (2, 3, 7, 8, 21, 22) . The emergence of breakthrough infections due to either C. glabrata with fks mutations or wild-type C. parapsilosis with a naturally occurring polymorphism in the fks gene has generally been related to prolonged echinocandin exposure (21) . Such infections appear to be sporadic and generally uncommon, but the modest shifts in the MIC distribution of echinocandins (micafungin) for C. glabrata demonstrated in the present study should be monitored more closely. a All isolates tested using CLSI broth microdilution methods. b Data compiled from the work of Pfaller et al. (13) .
